Glenmark Pharmaceuticals gets final approval for Propafenone Hydrochloride ER Capsules
From USFDA
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg, the generic version of Rythmol SR Capsules, 225 mg, 325 mg, and 425 mg, of GlaxoSmithKline, LLC.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 11 2017 | 9:13 AM IST